Ocugen, Inc. — Q2 2023 Form 10-Q Summary
Business context and reporting period
Ocugen is a pre-revenue biotechnology company developing gene therapies, cell therapies, biologics, and vaccines. The filing covers the three and six months ended June 30, 2023, with unaudited results. Key programs include OCU400, OCU410, OCU410ST, NeoCart, the inhaled mucosal vaccine platform, and OCU200.
Financial performance and position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | No revenue generated | No revenue generated |
| Research and development expense | $14.2 million | $23.7 million |
| General and administrative expense | $9.6 million | $17.8 million |
| Total operating expenses | $23.7 million | $41.5 million |
| Net loss | $22.9 million | $39.4 million |
| Net loss per share | $0.10 | $0.17 |
| Net cash used in operating activities | Not separately provided | $37.0 million |
Operating margins are not meaningful because the company has no product revenue. Cash and cash equivalents were $70.6 million at June 30, 2023, compared with $77.6 million at December 31, 2022. Marketable securities matured during the first six months, leaving no marketable securities balance at June 30.
Total assets were $89.0 million and stockholders’ equity was $70.3 million at June 30, 2023. Debt had a carrying value of $2.7 million, including $1.3 million classified as current. Operating lease liabilities totaled $3.8 million.
Cash flow from investing activities was $9.2 million, primarily reflecting $17.5 million of marketable-security maturities, partly offset by $4.4 million of property and equipment purchases. Financing activities provided $20.9 million, including equity proceeds and $0.5 million of additional EB-5 debt. Cash decreased by $7.0 million during the six-month period.
Material changes versus the prior comparable period
- Six-month net loss increased to $39.4 million from $37.5 million, while operating expenses increased to $41.5 million from $37.6 million.
- Six-month research and development expense increased $6.8 million, primarily from COVAXIN-related impairment and disposal costs, modifier gene therapy development, NeoCart activities, clinical readiness work for OCU410 and OCU410ST, and higher employee-related costs.
- General and administrative expense decreased $2.9 million, mainly because prior-year office-opening, pre-commercial, and professional-service costs did not recur.
- The company raised $14.8 million net from a May 2023 public offering of 30.0 million shares at $0.50 per share and $5.6 million net from its terminated at-the-market program. Shares outstanding increased materially, reaching approximately 256.5 million at June 30.
- The company wrote off the remaining $4.1 million advance for COVAXIN supply and recognized related disposal costs after determining that further development of the monovalent vaccine was not commercially viable in North America.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects to initiate a Phase 3 OCU400 trial near the end of 2023 or early 2024, subject to Phase 1/2 results and FDA discussions.
- FDA-cleared IND applications for OCU410 and OCU410ST; Phase 1/2 trials are targeted for initiation by the end of 2023.
- NeoCart’s Phase 3 trial is targeted for the second half of 2024, subject to preparation of the company’s GMP facility.
- The inhaled mucosal vaccine platform remains dependent on government funding; an IND submission is targeted for 2024 if funding is obtained.
- The FDA placed the OCU200 IND on clinical hold in April 2023 pending additional chemistry, manufacturing, and controls information.
- The filing states that current cash will not meet capital requirements for the 12 months following issuance of the financial statements. Management expects to require significant additional equity, debt, collaboration, licensing, government, or other funding. The filing includes substantial doubt about the company’s ability to continue as a going concern within one year.
- Potentially dilutive securities excluded from diluted EPS totaled approximately 18.8 million shares, including options, restricted stock units, warrants, and convertible preferred stock.
- A securities class action was dismissed with prejudice, but the lead plaintiff appealed. Related derivative litigation remains stayed. No loss accrual was recorded because a loss was not considered probable or reasonably estimable.
- After quarter-end, the company appointed a director as Interim Chief Accounting Officer and reconstituted its Audit Committee. The company also adopted amended bylaws addressing universal proxy requirements.
Most important facts for investors to verify
- Availability and terms of the additional financing required to fund operations beyond the next 12 months.
- Cash burn, projected runway, and whether planned clinical programs can proceed without delaying or reducing scope.
- OCU400 Phase 1/2 data, FDA feedback, and the timing and design of any Phase 3 trial.
- Resolution of the OCU200 clinical hold and progress toward OCU410 and OCU410ST trials.
- Government funding status for the inhaled mucosal vaccine platform.
- Potential dilution from future equity offerings, outstanding options, restricted stock units, warrants, and convertible preferred stock.
- Outcome of the securities class action appeal and related derivative proceedings.